Paperpal Prime Logo

Neurotherapeutics : Impact Factor & More

eISSN: 1878-7479pISSN: 1933-7213

Key Metrics

CiteScore
10
Eigenfactor
0.005 - 0.01
Impact Factor
5 - 10
SJR
Q1Pharmacology
SNIP
1.75
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Neurotherapeutics

Neurotherapeutics Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SPRINGER
Language English
Frequency Quarterly
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2004
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Neurotherapeutics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Neurotherapeutics

Current and emerging therapies in IDH-mutant glioma.
  • 1 Oct 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Focused ultrasound in epilepsy.
  • 8 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
NAcLat-DBS reduces GABAB expression of dopamine neurons to correct depressive symptoms in CMS mice.
  • 7 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder: Results from a double-blind, randomised, controlled trial (The Harmony study).
  • 6 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Intrabody B1 targeting TDP-43 modulates neuroinflammatory and metabolic pathways in a preclinical ALS model.
  • 6 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Extracellular vesicles: Navigating new frontiers in glioblastoma therapy.
  • 6 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Current and emerging therapies in IDH-mutant glioma.
  • 1 Oct 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Focused ultrasound in epilepsy.
  • 8 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
NAcLat-DBS reduces GABAB expression of dopamine neurons to correct depressive symptoms in CMS mice.
  • 7 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder: Results from a double-blind, randomised, controlled trial (The Harmony study).
  • 6 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Intrabody B1 targeting TDP-43 modulates neuroinflammatory and metabolic pathways in a preclinical ALS model.
  • 6 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Extracellular vesicles: Navigating new frontiers in glioblastoma therapy.
  • 6 Aug 2026
  • Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

FAQs on Neurotherapeutics